thalidomide has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is an active agent for the treatment of MALT lymphoma." | 1.48 | Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( Dolak, W; Kiesewetter, B; Kornauth, C; Lukas, J; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I, 2018) |
| "DLBCL rarely involves the orbit." | 1.48 | Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report. ( He, W; Min, X; Yang, X, 2018) |
| "Thalidomide treatment was associated with significant down-regulation of nuclear NF-κB expression levels in residual neoplastic cells and microenvironments of responsive tumors, but not in t(11;18)(q21;q21)-positive, thalidomide-refractory tumors." | 1.37 | t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. ( Chen, LT; Cheng, AL; Hsu, CH; Kuo, SH; Lin, CW; Tzeng, YS; Wu, MS; Yeh, KH, 2011) |
| "Pulmonary MALT lymphoma is a rare disease entity and generally follows an indolent clinical course." | 1.33 | Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide. ( Chott, A; Gisslinger, H; Kees, M; Metz-Schimmerl, S; Raderer, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiesewetter, B | 4 |
| Simonitsch-Klupp, I | 3 |
| Kornauth, C | 1 |
| Dolak, W | 3 |
| Lukas, J | 2 |
| Mayerhoefer, ME | 3 |
| Raderer, M | 6 |
| Thieblemont, C | 1 |
| Yang, X | 1 |
| Min, X | 1 |
| He, W | 1 |
| Troch, M | 3 |
| Willenbacher, E | 1 |
| Willenbacher, W | 1 |
| Egle, A | 1 |
| Neumeister, P | 1 |
| Voskova, D | 1 |
| Melchardt, T | 1 |
| Greil, R | 1 |
| Zielinski, C | 1 |
| Kuo, SH | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Hsu, CH | 1 |
| Wu, MS | 1 |
| Yeh, KH | 1 |
| Tzeng, YS | 1 |
| Chen, LT | 1 |
| Müllauer, L | 1 |
| Zielinski, CC | 1 |
| Kees, M | 1 |
| Metz-Schimmerl, S | 1 |
| Chott, A | 1 |
| Gisslinger, H | 1 |
| Crane, E | 1 |
| List, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type[NCT01611259] | Phase 2 | 50 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type[NCT00923663] | Phase 2 | 16 participants (Anticipated) | Interventional | 2009-07-31 | Recruiting | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
2 reviews available for thalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide | 2017 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mul | 2005 |
2 trials available for thalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lena | 2017 |
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; M | 2013 |
6 other studies available for thalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cerebrosides; Female; Humans; Immunohistoch | 2018 |
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematop | 2018 |
Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; | 2016 |
Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Conjunctival Neoplasms; Duodenal Neoplasms; Female; Humans; Lymphoma, B-Cell, Marginal | 2009 |
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.
Topics: Aged; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 18; Disease-Free Survival; Female; Human | 2011 |
Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide.
Topics: Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Thalidomide; Tomography, | 2005 |